Developer docs
API playgroundTry for free, no card

Search company profiles

Sirnaomics

Full company profile

uuid00008ps

Namestring
Sirnaomics
Legal namestring
Sirnaomics Ltd.
Websiteurl
sirnaomics.com
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Sirnaomics is a clinical-stage biopharmaceutical company (HKEX: 2257; founded 2007 in Maryland, USA) developing RNA interference (RNAi) therapeutics for oncology, medical aesthetics, and cardiometabolic diseases. The company is built on two proprietary delivery platforms: PNP (Polypeptide Nanoparticle), a histidine-lysine polypeptide system using a proton sponge mechanism that achieves 30%–50% endosomal escape efficiency and enables extrahepatic delivery to skin, adipose, muscle, eye, and solid tumors; and GalAhead™, a GalNAc-siRNA conjugate platform with programmable long-acting administration for liver-targeted indications. Its 14+ candidate pipeline includes core product STP705 (dual TGF-β1/COX-2 siRNA in PNP) in Phase II for cutaneous squamous cell carcinoma in situ (88.9% complete histological clearance) and in development for fat remodeling, plus STP707 (Phase I solid tumors), STP122G (Phase I anticoagulation, Factor XI), and an expanding GalAhead™/muRNA™ dual-target portfolio covering PCSK9, ANGPTL3, APOC3, AGT, TTR, and complement factors.

The company does not yet have any commercialized products. Revenue is expected to flow from product sales following regulatory approvals, supplemented by potential licensing/royalty income from strategic partners. Operations span US headquarters (Germantown, MD), Hong Kong (financing and IR hub), Suzhou (China R&D hub), Guangzhou (clinical manufacturing), Beijing (China clinical center), and Boston (US BD center), supporting a dual US/China clinical development strategy. STP705 has been granted FDA Orphan Drug Designation for cholangiocarcinoma and primary sclerosing cholangitis, creating regulatory exclusivity in those indications.

Sirnaomics' go-to-market is event- and partnership-driven: CEO Dr. H. Fai Poon presents at CPHI China, I-RNA Summit, and IMCAS World Summit; the company engages clinical trial sites globally and has entered strategic commercialization partnerships, most notably with Bloomage Biotech (HKD 138M investment, ~9.44% stake in 2025) to accelerate aesthetics, longevity, and regenerative medicine pipelines. Capital structure is anchored by the HKEX listing (December 2021, "Asia's first RNAi therapeutics stock"), a $105M Series E (2021), and ongoing insider/institutional backing including Dr. Poon's HK$58.9M subscription (2024) and an HK$8M HKSTP grant (2023).

Short descriptiontext

Sirnaomics is a clinical-stage biopharmaceutical company (HKEX: 2257; founded 2007) developing RNA interference therapeutics across oncology, medical aesthetics, and cardiometabolic diseases using two proprietary delivery platforms, PNP and GalAhead™.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGermantown, United States
HQ citystring
Germantown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices9 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNAi therapeutics, drug delivery platforms, oncology biopharmaceuticals, cardiovascular therapeutics, siRNA drug development
Industry5 codes
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
RNAi Therapeutics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1RNAi Therapeutic Pipeline Commercialization
TypeOne Time License
Description

As a clinical-stage biopharmaceutical company, Sirnaomics is developing multiple RNAi therapeutic candidates across oncology, medical aesthetics, and cardiovascular diseases. The company has not yet commercialized any products. Revenue will be generated through product sales following regulatory approvals. Key pipeline products include STP705 (Phase II for isSCC, BCC, fat remodeling), STP707 (Phase I for solid tumors), and STP122G (Phase I for anticoagulation).

sirnaomics.com
2Strategic Partnerships and Licensing
TypeLicensing Royalties
Description

The company may generate revenue through strategic partnerships, co-development agreements, and potential out-licensing of its proprietary delivery platforms (PNP, GalAhead™) and drug candidates to larger pharmaceutical companies. The collaboration with Bloomage Biotech represents a step toward pipeline commercialization in aesthetics and longevity.

prnewswire.com
3Government Grants and Subsidies
TypeManaged Services
Description

Sirnaomics receives government funding to support clinical development. The company received an HK$8 million subsidy from HKSTP to support clinical trials of STP122G for anticoagulation therapy.

en.prnasia.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1PNP Platform
Description

Polypeptide Nanoparticle delivery platform for extrahepatic RNAi delivery

sirnaomics.com
+1 more record
Core offering1 text field

Sirnaomics is a clinical-stage biopharmaceutical company developing RNA interference (RNAi) therapeutics for oncology, medical aesthetics, and cardiovascular/metabolic diseases. Its product portfolio comprises 14+ siRNA drug candidates built on two proprietary delivery platforms: PNP (Polypeptide Nanoparticle) for extrahepatic delivery and GalAhead™ (GalNAc-based) for liver-targeted, long-acting delivery. Core clinical asset STP705 (dual TGF-β1/COX-2 inhibitor) achieved 88.9% complete histological clearance in Phase IIb isSCC trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 88.9% complete histological clearance rate in isSCC Phase IIb trials
+4 more records
Product overview1 text field

Sirnaomics is a clinical-stage biopharmaceutical company (HKEX: 2257) specializing in RNA interference (RNAi) therapeutics with two proprietary delivery platforms: the PNP (Polypeptide Nanoparticle) platform for extrahepatic tissue targeting (skin, adipose, muscle, solid tumors) and the GalAhead™ (GalNAc) platform for liver-targeted delivery. The company's product portfolio includes multiple siRNA drug candidates spanning oncology (STP705, STP707, STP355, STP369), cardiovascular/metabolic diseases (STP122G, STP125G, STP136G, STP237G, STP247G, STP251G, STP271G, STP152G), and complement-mediated diseases (STP144G, STP145G, STP146G). Core product STP705 is in Phase II for skin cancers with 88.9% histological clearance rate. The company also operates an AODC platform for antibody-oligonucleotide conjugates and a muRNA™ dual-target technology for multi-target silencing.

Product and service15 records
1STP705
CategoryDrug Candidate — Oncology / Aesthetics
Description

Dual TGF-β1/COX-2 siRNA therapeutic using PNP delivery platform for intralesional administration; indicated for cutaneous squamous cell carcinoma in situ (isSCC), basal cell carcinoma (BCC), and fat remodeling for medical aesthetics. Achieved 88.9% complete histological clearance in Phase IIb isSCC trial with ≥24 months shelf-life stability at 2-8°C. Holds FDA Orphan Drug Designation for cholangiocarcinoma (CCA) and primary sclerosing cholangitis (PSC).

2STP707
CategoryDrug Candidate — Oncology
Description

TGF-β1/COX-2 dual inhibitor using PNP-IV delivery platform for intravenous administration; indicated for solid tumors and liver cancer. Currently in Phase I clinical stage.

3STP355
CategoryDrug Candidate — Oncology
Description

siRNA treatment targeting TGF-β1 and VEGFR2 proteins using PNP delivery platform; indicated for breast cancer, melanoma, and colorectal cancer. Preclinical stage.

4STP369
CategoryDrug Candidate — Oncology
Description

siRNA treatment targeting BCL-xL and MCL-1 proteins using PNP delivery platform; indicated for head and neck cancer and bladder cancer, with exploration of combination therapy with platinum-based chemotherapy cisplatin. Preclinical stage.

5STP122G
CategoryDrug Candidate — Cardiovascular / Anticoagulation
Description

Factor XI-targeted siRNA using GalAhead™ (GalNAc) delivery platform for subcutaneous administration; indicated as anticoagulant for stroke patients and orthopedic surgery patients. Early clinical stage with U.S. IND submitted.

6STP125G
CategoryDrug Candidate — Cardiovascular / Metabolic
Description

APOC3-targeted siRNA using GalAhead™ platform for treating hypertriglyceridemia and familial hypertriglyceridemia. Preclinical stage.

7STP144G
CategoryDrug Candidate — Complement-Mediated Diseases
Description

Complement Factor B-targeted siRNA using GalAhead™ platform for complement-mediated diseases. Preclinical stage.

8STP145G
CategoryDrug Candidate — Complement-Mediated Diseases
Description

Complement Factor C5-targeted siRNA using GalAhead™ platform for complement-mediated diseases. Preclinical stage.

9STP146G
CategoryDrug Candidate — Complement-Mediated Diseases
Description

Complement Factor C3-targeted siRNA using GalAhead™ platform for complement-mediated diseases. Preclinical stage.

10STP152G
CategoryDrug Candidate — Cardiovascular / Metabolic
Description

TTR (transthyretin)-targeted siRNA using GalAhead™ platform for ATTR amyloidosis. Preclinical stage.

11STP136G
CategoryDrug Candidate — Cardiovascular / Hypertension
Description

AGT (angiotensinogen)-targeted siRNA using GalAhead™ platform for hypertension. Preclinical stage.

12STP247G
CategoryDrug Candidate — Complement-Mediated Diseases
Description

Dual-target siRNA targeting Complement Factor CFB/C5 using GalAhead™ muRNA platform for subcutaneous administration; indicated for complement-mediated diseases. Preclinical stage.

13STP251G
CategoryDrug Candidate — Cardiovascular / Metabolic
Description

Dual-target siRNA targeting APOC3/TMPRSS6 using GalAhead™ muRNA platform for subcutaneous administration; indicated for hemochromatosis and hypertriglyceridemia. Preclinical stage.

14STP237G
CategoryDrug Candidate — Cardiovascular / Metabolic
Description

Dual-target siRNA targeting AGT/APOC3 using GalAhead™ platform; indicated for hypertension and hypertriglyceridemia. Preclinical stage.

15STP271G
CategoryDrug Candidate — Cardiovascular / Metabolic
Description

Dual-target siRNA targeting PCSK9/ANGPTL3 using GalAhead™ platform; indicated for hyperlipidemia/hypertriglyceridemia. Preclinical stage.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

Joint application for Lingang Laboratory scientific research task project titled 'Construction of Innovative One Drug, Two Targets muRNA Nucleic Acid Drugs and Preclinical Research Targeting Dyslipidemia'. Project focuses on PCSK9, ANGPTL3, and DGAT2 targets for treating dyslipidemia using Sirnaomics' muRNA dual-target RNAi technology and GalAhead delivery system.

2Bloomage Biotech
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-08
Description

Strategic equity investment of approximately HKD 138 million giving Bloomage about 9.44% of Sirnaomics' shares. Investment aims to accelerate development in aesthetics, longevity, regenerative medicine, and other pipelines through collaboration on delivery platforms and biologics. Represents a key strategic partnership for pipeline commercialization in specific therapeutic areas.

prnewswire.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeRegional player
Description

China-based RNAi therapeutics company developing siRNA candidates for cardiovascular, metabolic and infectious diseases using proprietary RIBO-GalSTAR® GalNAc delivery platform. Comparable to Sirnaomics as an Asia-based RNAi competitor with similar cardiometabolic focus and platform-based approach.

TypeDirect peer
Description

Clinical-stage RNA therapeutics company using stereopure oligonucleotide chemistry and siRNA/ASO platforms with extrahepatic and CNS delivery ambitions. Comparable to Sirnaomics in platform-driven RNA therapeutics strategy, pursuit of tissues outside the liver, and early-to-mid clinical stage development.

TypeDirect peer
Description

The global leader in RNAi therapeutics with multiple commercialized assets (Onpattro, Givlaari, Oxlumo, Amvuttra) primarily using GalNAc liver-targeted delivery. Sirnaomics competes with Alnylam in RNAi platform technology, cardiometabolic indications (PCSK9, TTR, APOC3) and overall siRNA chemistry/CMC know-how, though Sirnaomics differentiates on extrahepatic delivery via PNP.

TypeDirect peer
Description

China-based clinical-stage RNAi therapeutics company developing siRNA candidates for neuromuscular and rare diseases using proprietary delivery approaches. Comparable to Sirnaomics as an Asia-headquartered RNAi platform competitor, particularly relevant given Sirnaomics' own US-China operations.

TypeBroad incumbent
Description

Global biopharmaceutical company best known for mRNA COVID vaccines, with expanding pipeline into cancer immunotherapies and RNA therapeutics. Comparable to Sirnaomics as a broader RNA medicines player, though BioNTech's commercial scale, mRNA focus and immuno-oncology pipeline make it a broader incumbent rather than a direct RNAi competitor.

TypeDirect peer
Description

Clinical-stage RNA medicines company developing both mRNA vaccines/therapeutics and siRNA candidates with proprietary LUNAR® delivery technology. Comparable to Sirnaomics in combining siRNA and mRNA delivery ambitions and platform-based pipeline strategy.

TypeDirect peer
Description

Clinical-stage RNAi therapeutics company with multiple partnered programs in cardiometabolic, liver and pulmonary indications, using both GalNAc and TRiM™ delivery platforms. Sirnaomics and Arrowhead overlap on liver-targeted GalNAc siRNA development (PCSK9, APOC3, AGT), pipeline breadth and clinical stage, making Arrowhead one of the closest comparables for the GalAhead™ platform.

TypeDirect peer
Description

Clinical-stage RNAi therapeutics company developing GalNAc-conjugated siRNAs for cardiovascular and rare diseases (notably SLN360 for LP(a) and SLN124 for iron overload). Directly comparable to Sirnaomics on GalAhead™-style liver-targeted siRNA delivery, cardiometabolic focus, and clinical stage.

TypeBroad incumbent
Description

Established antisense oligonucleotide (ASO) leader with multiple commercialized products (Spinraza, Tegsedi, Waylivra) and a broader RNA-targeted drug portfolio. Comparable to Sirnaomics as a pioneer in RNA-targeted therapeutics but operates with a different chemistry (ASO vs siRNA) and broader indication coverage.

TypeOthers
Description

Acquired by Novo Nordisk in 2021, Dicerna was a clinical-stage RNAi company developing GalNAc-conjugated siRNAs for cardiometabolic and rare diseases — closely mirroring the GalAhead™ platform strategy. Now operates within Novo Nordisk's broader RNAi and cardiometabolic pipeline, representing the strategic acquirer profile Sirnaomics' liver-targeted assets could attract.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment4 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sirnaomics

RNAi Therapeuticssirnaomics.com

Sirnaomics is a clinical-stage biopharmaceutical company (HKEX: 2257; founded 2007) developing RNA interference therapeutics across oncology, medical aesthetics, and cardiometabolic diseases using two proprietary delivery platforms, PNP and GalAhead™.

What Sirnaomics does

Sirnaomics is a clinical-stage biopharmaceutical company (HKEX: 2257; founded 2007 in Maryland, USA) developing RNA interference (RNAi) therapeutics for oncology, medical aesthetics, and cardiometabolic diseases. The company is built on two proprietary delivery platforms: PNP (Polypeptide Nanoparticle), a histidine-lysine polypeptide system using a proton sponge mechanism that achieves 30%–50% endosomal escape efficiency and enables extrahepatic delivery to skin, adipose, muscle, eye, and solid tumors; and GalAhead™, a GalNAc-siRNA conjugate platform with programmable long-acting administration for liver-targeted indications. Its 14+ candidate pipeline includes core product STP705 (dual TGF-β1/COX-2 siRNA in PNP) in Phase II for cutaneous squamous cell carcinoma in situ (88.9% complete histological clearance) and in development for fat remodeling, plus STP707 (Phase I solid tumors), STP122G (Phase I anticoagulation, Factor XI), and an expanding GalAhead™/muRNA™ dual-target portfolio covering PCSK9, ANGPTL3, APOC3, AGT, TTR, and complement factors.

The company does not yet have any commercialized products. Revenue is expected to flow from product sales following regulatory approvals, supplemented by potential licensing/royalty income from strategic partners. Operations span US headquarters (Germantown, MD), Hong Kong (financing and IR hub), Suzhou (China R&D hub), Guangzhou (clinical manufacturing), Beijing (China clinical center), and Boston (US BD center), supporting a dual US/China clinical development strategy. STP705 has been granted FDA Orphan Drug Designation for cholangiocarcinoma and primary sclerosing cholangitis, creating regulatory exclusivity in those indications.

Sirnaomics' go-to-market is event- and partnership-driven: CEO Dr. H. Fai Poon presents at CPHI China, I-RNA Summit, and IMCAS World Summit; the company engages clinical trial sites globally and has entered strategic commercialization partnerships, most notably with Bloomage Biotech (HKD 138M investment, ~9.44% stake in 2025) to accelerate aesthetics, longevity, and regenerative medicine pipelines. Capital structure is anchored by the HKEX listing (December 2021, "Asia's first RNAi therapeutics stock"), a $105M Series E (2021), and ongoing insider/institutional backing including Dr. Poon's HK$58.9M subscription (2024) and an HK$8M HKSTP grant (2023).

Sirnaomics firmographics

Firmographics
Name
Sirnaomics
Legal name
Sirnaomics Ltd.
Website
https://sirnaomics.com
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Sirnaomics is a clinical-stage biopharmaceutical company (HKEX: 2257; founded 2007) developing RNA interference therapeutics across oncology, medical aesthetics, and cardiometabolic diseases using two proprietary delivery platforms, PNP and GalAhead™.
Ownership category
akta.pro rank

Sirnaomics industry classification

Industry
Product category
RNAi Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • RNAi therapeutics
  • Drug delivery platforms
  • Oncology biopharmaceuticals
  • Cardiovascular therapeutics
  • SiRNA drug development

Where Sirnaomics is headquartered

Location

Headquarters

HQ city
Germantown
HQ country
United States
HQ region
North America

Offices9 records

Markets served

Sirnaomics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. RNAi Therapeutic Pipeline Commercialization: As a clinical-stage biopharmaceutical company, Sirnaomics is developing multiple RNAi therapeutic candidates across oncology, medical aesthetics, and cardiovascular diseases. The company has not yet commercialized any products. Revenue will be generated through product sales following regulatory approvals. Key pipeline products include STP705 (Phase II for isSCC, BCC, fat remodeling), STP707 (Phase I for solid tumors), and STP122G (Phase I for anticoagulation).
  2. Strategic Partnerships and Licensing: The company may generate revenue through strategic partnerships, co-development agreements, and potential out-licensing of its proprietary delivery platforms (PNP, GalAhead™) and drug candidates to larger pharmaceutical companies. The collaboration with Bloomage Biotech represents a step toward pipeline commercialization in aesthetics and longevity.
  3. Government Grants and Subsidies: Sirnaomics receives government funding to support clinical development. The company received an HK$8 million subsidy from HKSTP to support clinical trials of STP122G for anticoagulation therapy.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Sirnaomics product offering

Product offering

Core offering

Sirnaomics is a clinical-stage biopharmaceutical company developing RNA interference (RNAi) therapeutics for oncology, medical aesthetics, and cardiovascular/metabolic diseases. Its product portfolio comprises 14+ siRNA drug candidates built on two proprietary delivery platforms: PNP (Polypeptide Nanoparticle) for extrahepatic delivery and GalAhead™ (GalNAc-based) for liver-targeted, long-acting delivery. Core clinical asset STP705 (dual TGF-β1/COX-2 inhibitor) achieved 88.9% complete histological clearance in Phase IIb isSCC trials.

Product overview

Sirnaomics is a clinical-stage biopharmaceutical company (HKEX: 2257) specializing in RNA interference (RNAi) therapeutics with two proprietary delivery platforms: the PNP (Polypeptide Nanoparticle) platform for extrahepatic tissue targeting (skin, adipose, muscle, solid tumors) and the GalAhead™ (GalNAc) platform for liver-targeted delivery. The company's product portfolio includes multiple siRNA drug candidates spanning oncology (STP705, STP707, STP355, STP369), cardiovascular/metabolic diseases (STP122G, STP125G, STP136G, STP237G, STP247G, STP251G, STP271G, STP152G), and complement-mediated diseases (STP144G, STP145G, STP146G). Core product STP705 is in Phase II for skin cancers with 88.9% histological clearance rate. The company also operates an AODC platform for antibody-oligonucleotide conjugates and a muRNA™ dual-target technology for multi-target silencing.

Differentiator

Problem solved

Functional benefit

Brands

  • PNP Platform: Polypeptide Nanoparticle delivery platform for extrahepatic RNAi delivery
  • GalAHead™

Products and services

  • STP705 Dual TGF-β1/COX-2 siRNA therapeutic using PNP delivery platform for intralesional administration; indicated for cutaneous squamous cell carcinoma in situ (isSCC), basal cell carcinoma (BCC), and fat remodeling for medical aesthetics. Achieved 88.9% complete histological clearance in Phase IIb isSCC trial with ≥24 months shelf-life stability at 2-8°C. Holds FDA Orphan Drug Designation for cholangiocarcinoma (CCA) and primary sclerosing cholangitis (PSC).
  • STP707 TGF-β1/COX-2 dual inhibitor using PNP-IV delivery platform for intravenous administration; indicated for solid tumors and liver cancer. Currently in Phase I clinical stage.
  • STP355 siRNA treatment targeting TGF-β1 and VEGFR2 proteins using PNP delivery platform; indicated for breast cancer, melanoma, and colorectal cancer. Preclinical stage.
  • STP369 siRNA treatment targeting BCL-xL and MCL-1 proteins using PNP delivery platform; indicated for head and neck cancer and bladder cancer, with exploration of combination therapy with platinum-based chemotherapy cisplatin. Preclinical stage.
  • STP122G Factor XI-targeted siRNA using GalAhead™ (GalNAc) delivery platform for subcutaneous administration; indicated as anticoagulant for stroke patients and orthopedic surgery patients. Early clinical stage with U.S. IND submitted.
  • STP125G APOC3-targeted siRNA using GalAhead™ platform for treating hypertriglyceridemia and familial hypertriglyceridemia. Preclinical stage.
  • STP144G Complement Factor B-targeted siRNA using GalAhead™ platform for complement-mediated diseases. Preclinical stage.
  • STP145G Complement Factor C5-targeted siRNA using GalAhead™ platform for complement-mediated diseases. Preclinical stage.
  • STP146G Complement Factor C3-targeted siRNA using GalAhead™ platform for complement-mediated diseases. Preclinical stage.
  • STP152G TTR (transthyretin)-targeted siRNA using GalAhead™ platform for ATTR amyloidosis. Preclinical stage.
  • STP136G AGT (angiotensinogen)-targeted siRNA using GalAhead™ platform for hypertension. Preclinical stage.
  • STP247G Dual-target siRNA targeting Complement Factor CFB/C5 using GalAhead™ muRNA platform for subcutaneous administration; indicated for complement-mediated diseases. Preclinical stage.
  • STP251G Dual-target siRNA targeting APOC3/TMPRSS6 using GalAhead™ muRNA platform for subcutaneous administration; indicated for hemochromatosis and hypertriglyceridemia. Preclinical stage.
  • STP237G Dual-target siRNA targeting AGT/APOC3 using GalAhead™ platform; indicated for hypertension and hypertriglyceridemia. Preclinical stage.
  • STP271G Dual-target siRNA targeting PCSK9/ANGPTL3 using GalAhead™ platform; indicated for hyperlipidemia/hypertriglyceridemia. Preclinical stage.

Quantifiable outcome

  • 88.9% complete histological clearance rate in isSCC Phase IIb trials
  • +4 more outcomes

Companies that use Sirnaomics

Customer profile

Segments4 records

Ideal customer profiles3 records

Sirnaomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Sirnaomics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered strategic and core.

  • Peking University (Professor Tang Xinjing's team)strategicStrategic or Co-development Partner · 22 April 2026Joint application for Lingang Laboratory scientific research task project titled 'Construction of Innovative One Drug, Two Targets muRNA Nucleic Acid Drugs and Preclinical Research Targeting Dyslipidemia'. Project focuses on PCSK9, ANGPTL3, and DGAT2 targets for treating dyslipidemia using Sirnaomics' muRNA dual-target RNAi technology and GalAhead delivery system.
  • Bloomage BiotechcoreStrategic or Co-development Partner · 8 September 2025Strategic equity investment of approximately HKD 138 million giving Bloomage about 9.44% of Sirnaomics' shares. Investment aims to accelerate development in aesthetics, longevity, regenerative medicine, and other pipelines through collaboration on delivery platforms and biologics. Represents a key strategic partnership for pipeline commercialization in specific therapeutic areas.

Scale indicators12 records

Recent moves7 records

Expansion highlights5 records

Sirnaomics competitors and assessment

Company assessment

Regional players

  • Suzhou Ribo Life Science: China-based RNAi therapeutics company developing siRNA candidates for cardiovascular, metabolic and infectious diseases using proprietary RIBO-GalSTAR® GalNAc delivery platform. Comparable to Sirnaomics as an Asia-based RNAi competitor with similar cardiometabolic focus and platform-based approach.

Direct peers

  • Wave Life Sciences: Clinical-stage RNA therapeutics company using stereopure oligonucleotide chemistry and siRNA/ASO platforms with extrahepatic and CNS delivery ambitions. Comparable to Sirnaomics in platform-driven RNA therapeutics strategy, pursuit of tissues outside the liver, and early-to-mid clinical stage development.
  • Alnylam Pharmaceuticals: The global leader in RNAi therapeutics with multiple commercialized assets (Onpattro, Givlaari, Oxlumo, Amvuttra) primarily using GalNAc liver-targeted delivery. Sirnaomics competes with Alnylam in RNAi platform technology, cardiometabolic indications (PCSK9, TTR, APOC3) and overall siRNA chemistry/CMC know-how, though Sirnaomics differentiates on extrahepatic delivery via PNP.
  • Ractigen Therapeutics: China-based clinical-stage RNAi therapeutics company developing siRNA candidates for neuromuscular and rare diseases using proprietary delivery approaches. Comparable to Sirnaomics as an Asia-headquartered RNAi platform competitor, particularly relevant given Sirnaomics' own US-China operations.
  • Arcturus Therapeutics: Clinical-stage RNA medicines company developing both mRNA vaccines/therapeutics and siRNA candidates with proprietary LUNAR® delivery technology. Comparable to Sirnaomics in combining siRNA and mRNA delivery ambitions and platform-based pipeline strategy.
  • Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company with multiple partnered programs in cardiometabolic, liver and pulmonary indications, using both GalNAc and TRiM™ delivery platforms. Sirnaomics and Arrowhead overlap on liver-targeted GalNAc siRNA development (PCSK9, APOC3, AGT), pipeline breadth and clinical stage, making Arrowhead one of the closest comparables for the GalAhead™ platform.
  • Silence Therapeutics: Clinical-stage RNAi therapeutics company developing GalNAc-conjugated siRNAs for cardiovascular and rare diseases (notably SLN360 for LP(a) and SLN124 for iron overload). Directly comparable to Sirnaomics on GalAhead™-style liver-targeted siRNA delivery, cardiometabolic focus, and clinical stage.

Broad incumbents

  • BioNTech: Global biopharmaceutical company best known for mRNA COVID vaccines, with expanding pipeline into cancer immunotherapies and RNA therapeutics. Comparable to Sirnaomics as a broader RNA medicines player, though BioNTech's commercial scale, mRNA focus and immuno-oncology pipeline make it a broader incumbent rather than a direct RNAi competitor.
  • Ionis Pharmaceuticals: Established antisense oligonucleotide (ASO) leader with multiple commercialized products (Spinraza, Tegsedi, Waylivra) and a broader RNA-targeted drug portfolio. Comparable to Sirnaomics as a pioneer in RNA-targeted therapeutics but operates with a different chemistry (ASO vs siRNA) and broader indication coverage.

Others

  • Dicerna Pharmaceuticals (Novo Nordisk): Acquired by Novo Nordisk in 2021, Dicerna was a clinical-stage RNAi company developing GalNAc-conjugated siRNAs for cardiometabolic and rare diseases — closely mirroring the GalAhead™ platform strategy. Now operates within Novo Nordisk's broader RNAi and cardiometabolic pipeline, representing the strategic acquirer profile Sirnaomics' liver-targeted assets could attract.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Sirnaomics social profiles

Digital presence

Sirnaomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sirnaomics leadership team

Management profile

Number of profiles

Profiles7 records

Sirnaomics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Sirnaomics funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sirnaomics M&A and investment

M&A and investment

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sirnaomics

What does Sirnaomics do?

Sirnaomics is a clinical-stage biopharmaceutical company developing RNA interference (RNAi) therapeutics for oncology, medical aesthetics, and cardiovascular/metabolic diseases. Its product portfolio comprises 14+ siRNA drug candidates built on two proprietary delivery platforms: PNP (Polypeptide Nanoparticle) for extrahepatic delivery and GalAhead™ (GalNAc-based) for liver-targeted, long-acting delivery. Core clinical asset STP705 (dual TGF-β1/COX-2 inhibitor) achieved 88.9% complete histological clearance in Phase IIb isSCC trials.

Is Sirnaomics a public or private company?

Sirnaomics is a public company. It is classified as public and is currently operating.

When was Sirnaomics founded?

Sirnaomics was founded in 2007. It employs 11 to 50 people.

Where is Sirnaomics based?

Sirnaomics is headquartered in Germantown, United States, in the North America region.

How does Sirnaomics make money?

Three revenue lines are on record. RNAi Therapeutic Pipeline Commercialization is the primary driver. The others are strategic Partnerships and Licensing and government Grants and Subsidies.

Who are Sirnaomics's main competitors?

Suzhou Ribo Life Science is listed as a regional player. Direct peers are Wave Life Sciences, Alnylam Pharmaceuticals, Ractigen Therapeutics, Arcturus Therapeutics, Arrowhead Pharmaceuticals and Silence Therapeutics. Broad incumbents are BioNTech and Ionis Pharmaceuticals. Dicerna Pharmaceuticals (Novo Nordisk) is listed as an others.

Does Sirnaomics have an API?

No public API is recorded for Sirnaomics.

What industry is Sirnaomics in?

Sirnaomics's product category is RNAi Therapeutics. Its primary akta.pro industry code is HLAAADAB, siRNA Therapeutics (gene silencing), with a secondary code of HLAAADAE, RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialPrimary Sclerosing Cholangitis Drugs In Development 2026: Pipeline Therapies, Ongoing Trials, And Companies Driving Innovation Engitix, GRI Bio, Qing Bile Therapeutics, Sirnaomics, Cascade PharmaPrimary sclerosing cholangitis (PSC) pipeline therapies are advancing, with Mirum's volixibat achieving a primary endpoint in its Phase IIb VISTAS trial and receiving FDA Breakthrough and Orphan Drug designations. Other candidates include norucholic acid, nebokitug, and elafibranor, with several companies planning Phase III trials or regulatory filings in 2026-2027.openPR.comRNAi Therapeutics Market Set to Record USD 8.80 billion by 2033 - Key Leaders - Benitec Biopharma, Thermo Fisher Scientific Inc and Sirnaomics Inc, Dicerna Pharmaceuticals, Silence TherapeuticsDataM Intelligence released a market research report on the RNAi Therapeutics sector, projecting growth from USD 2.60 billion in 2024 to USD 8.80 billion by 2033, representing a compound annual growth rate of 14.6%. The report highlights two notable mergers and acquisitions: Novartis completed its acquisition of Avidity Biosciences in February 2026, and Cyclerion Therapeutics announced an all-stock merger with Korsana Biosciences in April 2026. Regional market analysis shows North America dominating at 52% share, followed by Europe at 24% and Asia-Pacific at 16%.openPR.comTGFB Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, Leading Companies, and Future OutlookDelveInsight published a market research report covering the TGF-beta inhibitors pipeline landscape, identifying 25+ companies developing 30+ pipeline therapies across various clinical stages. The report profiles specific drug candidates including Trabedersen (Oncotelic, Phase III), KER-050 (Keros Therapeutics, Phase II), and STP705 (Sirnaomics, Phase II) targeting treatments for oncology and hematologic conditions. The research covers therapeutic assessments by product type, route of administration, and molecule type on a global scale.MarketScreenerSirnaomics Unit's STP707 Shows Clinical Activity in Phase 1 Cancer Trial; Shares Jump 2%Sirnaomics Ltd.'s subsidiary announced that its drug candidate STP707 demonstrated clinical activity in a Phase 1 cancer trial, representing a positive development for the company's RNAi-based oncology pipeline. Following the announcement, shares of Sirnaomics Ltd. rose approximately 2%, reflecting investor optimism around the trial results. STP707 is being developed as a sterile drug product targeting solid tumors, including liver cancer, metastatic cutaneous squamous-cell skin cancer, and non-small cell lung cancer.PR NewswireSirnaomics Announces Strategic Equity Investment by Bloomage Biotech to Jointly Advance Next-Generation Life Science PipelinesBloomage Biotech invested approximately HKD 138 million in Sirnaomics' strategic placement, acquiring about 9.44% of the company. The partnership aims to accelerate Sirnaomics' aesthetics, longevity, and regenerative medicine pipelines, including the STP705 fat reduction program. Both parties will co-develop precision-delivery solutions combining Sirnaomics' RNAi platforms with Bloomage's biomanufacturing expertise.MarketScreenerSirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and DevelopmentSirnaomics Ltd. announced a subscription agreement with Dr. Poon Hung Fai to issue 17,527,696 new shares at HK$3.36 per share, raising approximately HK$58.9 million in gross proceeds. The capital injection is intended to support the biopharmaceutical company's business growth, drug R&D, and strategic planning. This transaction also aims to optimize Sirnaomics' shareholding structure by leveraging Dr. Poon's experience in the biotechnology sector.PR NewswireSirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and DevelopmentSirnaomics Ltd. has entered into a subscription agreement with Dr. Poon Hung Fai to issue 17,527,696 subscription shares at approximately HK$3.36 per share, raising about HK$58.9 million. This capital injection is expected to enhance the Group's business development, drug research, and development capabilities. The partnership aims to advance Sirnaomics' product offerings and solidify its market position.YahooGore Range Capital Partners with Sirnaomics to Create Sagesse Bio to Advance RNAi Therapeutics for Focal Fat Reduction and Aesthetic Body ContouringGore Range Capital and Sirnaomics formed Sagesse Bio to develop RNAi therapeutics for focal fat reduction and aesthetic body contouring. The medical aesthetics market is projected to grow from $20 billion to $27 billion by 2028. Sagesse Bio will begin clinical evaluation of its product candidate SGY-101.PR NewswireSirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer PatientsSirnaomics announced the completion of its Phase I clinical study for STP707, an siRNA drug candidate targeting TGF-β1 and COX-2, demonstrating strong safety profile and stable disease activity in 11 heavily pre-treated pancreatic cancer patients across six dose escalation cohorts in the U.S. The study showed no treatment-related adverse events in pancreatic patients, with the maximum tolerated dose not reached even at 48mg, and an average stable disease duration of 92 days across all doses. This marks the first time a polypeptide nanoparticle-based siRNA cancer therapeutic has shown early positive safety and efficacy results in late-stage pancreatic cancer, warranting further clinical investigation either as monotherapy or in combination with immune checkpoint inhibitors.